APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dengue Vaccines

Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.

Selected research

Market Analysis & Forecast

Global Dengue Vaccines Market Analysis and Forecast 2026-2032

27 December 2025190 pages

Choose your research edition.

Industry ResearchDengue Vaccines Industry Research Report 2026102 pages · $2,950 USDIndustry Growth & TrendsGlobal Dengue Vaccines Industry Growth and Trends Forecast to 203260 pages · $3,450 USDMarket StructureGlobal Dengue Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dengue Vaccines Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Dengue Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.

The only one version which is commercially available now, known as Dengvaxia and produced by Sanofi, don't has enough efficacy. While there are several vaccines are on trial now. TAK-003, developed by Takeda is one stride closer to reaching the sizable market waiting for dengue vaccines as it reports positive top-line results from a massive Phase III trial.

Report Includes

Read the full market overview

This report presents an overview of global market for Dengue Vaccines, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Dengue Vaccines, also provides the revenue of main regions and countries. Of the upcoming market potential for Dengue Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Dengue Vaccines revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Dengue Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Dengue Vaccines revenue, projected growth trends, production technology, application and end-user industry.

Dengue Vaccines Segment by Company

Sanofi

Takeda

Dengue Vaccines Segment by Type

Dengvaxia

TAK-003

Others

Dengue Vaccines Segment by Application

Public Sector

Private Sector

Dengue Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dengue Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dengue Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dengue Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Dengue Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Dengue Vaccines company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dengue Vaccines revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Dengue Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Dengvaxia Major Player Table 3. TAK-003 Major Player Table 4. Others Major Player Table 5. Global Dengue Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Public Sector Major Player Table 7. Private Sector Major Player Table 8. Dengue Vaccines Industry Trends Table 9. Dengue Vaccines Industry Drivers Table 10. Dengue Vaccines Industry Opportunities and Challenges Table 11. Dengue Vaccines Industry Restraints Table 12. Global Dengue Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Dengue Vaccines Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Dengue Vaccines Market Share by Region (2021-2026) Table 15. Global Dengue Vaccines Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Dengue Vaccines Market Share by Region (2027-2032) Table 17. Global Dengue Vaccines Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Dengue Vaccines Revenue Market Share by Players (2021-2026) Table 19. Global Dengue Vaccines Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Dengue Vaccines Key Players Headquarters & Area Served Table 21. Global Dengue Vaccines Players, Product Type & Application Table 22. Global Dengue Vaccines Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Dengue Vaccines by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Dengue Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Dengue Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Dengue Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Dengue Vaccines Revenue Market Share by Type (2021-2026) Table 29. Global Dengue Vaccines Revenue Market Share by Type (2027-2032) Table 30. Global Dengue Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Dengue Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Dengue Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Dengue Vaccines Revenue Market Share by Application (2021-2026) Table 34. Global Dengue Vaccines Revenue Market Share by Application (2027-2032) Table 35. Sanofi Company Information Table 36. Sanofi Business Overview Table 37. Sanofi Dengue Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Sanofi Dengue Vaccines Product Portfolio Table 39. Sanofi Recent Development Table 40. Takeda Company Information Table 41. Takeda Business Overview Table 42. Takeda Dengue Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Takeda Dengue Vaccines Product Portfolio Table 44. Takeda Recent Development Table 45. North America Dengue Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 46. North America Dengue Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 47. North America Dengue Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 48. North America Dengue Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 49. North America Dengue Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 50. North America Dengue Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 51. North America Dengue Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 52. Europe Dengue Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 53. Europe Dengue Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 54. Europe Dengue Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 55. Europe Dengue Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 56. Europe Dengue Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 57. Europe Dengue Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 58. Europe Dengue Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 59. China Dengue Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 60. China Dengue Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 61. China Dengue Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 62. China Dengue Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 63. Asia Dengue Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 64. Asia Dengue Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 65. Asia Dengue Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 66. Asia Dengue Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 67. Asia Dengue Vaccines Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 68. Asia Dengue Vaccines Revenue by Region (US$ Million) & (2021-2026) Table 69. Asia Dengue Vaccines Revenue by Region (US$ Million) & (2027-2032) Table 70. SAMEA Dengue Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 71. SAMEA Dengue Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 72. SAMEA Dengue Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 73. SAMEA Dengue Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 74. SAMEA Dengue Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. SAMEA Dengue Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 76. SAMEA Dengue Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Dengue Vaccines Image Figure 2. Global Dengue Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dengue Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Dengvaxia Image Figure 5. TAK-003 Image Figure 6. Others Image Figure 7. Global Dengue Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Dengue Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 9. Public Sector Image Figure 10. Private Sector Image Figure 11. Global Dengue Vaccines Market Size (US$ Million) & (2021-2032) Figure 12. Global Dengue Vaccines Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Dengue Vaccines Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Dengue Vaccines Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Dengue Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Dengue Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Dengue Vaccines Revenue Market Share by Type (2021-2032) Figure 19. Global Dengue Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Dengue Vaccines Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Dengue Vaccines Revenue Market Share by Application (2021-2032) Figure 22. North America Dengue Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Dengue Vaccines Revenue Share by Type (2021-2032) Figure 24. North America Dengue Vaccines Revenue Share by Application (2021-2032) Figure 25. North America Dengue Vaccines Revenue Share by Country (2021-2032) Figure 26. United States Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Dengue Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Dengue Vaccines Revenue Share by Type (2021-2032) Figure 31. Europe Dengue Vaccines Revenue Share by Application (2021-2032) Figure 32. Europe Dengue Vaccines Revenue Share by Country (2021-2032) Figure 33. Germany Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Dengue Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Dengue Vaccines Revenue Share by Type (2021-2032) Figure 43. China Dengue Vaccines Revenue Share by Application (2021-2032) Figure 44. Asia Dengue Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Dengue Vaccines Revenue Share by Type (2021-2032) Figure 46. Asia Dengue Vaccines Revenue Share by Application (2021-2032) Figure 47. Asia Dengue Vaccines Revenue Share by Region (2021-2032) Figure 48. Japan Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Dengue Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Dengue Vaccines Revenue Share by Type (2021-2032) Figure 56. SAMEA Dengue Vaccines Revenue Share by Application (2021-2032) Figure 57. SAMEA Dengue Vaccines Revenue Share by Country (2021-2032) Figure 58. Brazil Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Dengue Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Dengvaxia
  • TAK-003
  • Others
Applications
  • Public Sector
  • Private Sector
Companies covered
  • Sanofi
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Dengue Vaccines Market by Type
  3. 1.2.1 Global Dengue Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Dengvaxia
  5. 1.2.3 TAK-003
  6. 1.2.4 Others
  7. 1.3 Dengue Vaccines Market by Application
  8. 1.3.1 Global Dengue Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Public Sector
  10. 1.3.3 Private Sector
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Dengue Vaccines Market Dynamics
  1. 2.1 Dengue Vaccines Industry Trends
  2. 2.2 Dengue Vaccines Industry Drivers
  3. 2.3 Dengue Vaccines Industry Opportunities and Challenges
  4. 2.4 Dengue Vaccines Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Dengue Vaccines Market Perspective (2021-2032)
  2. 3.2 Global Dengue Vaccines Growth Trends by Region
  3. 3.2.1 Global Dengue Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Dengue Vaccines Market Size by Region (2021-2026)
  5. 3.2.3 Global Dengue Vaccines Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Dengue Vaccines Revenue by Players
  2. 4.1.1 Global Dengue Vaccines Revenue by Players (2021-2026)
  3. 4.1.2 Global Dengue Vaccines Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Dengue Vaccines Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Dengue Vaccines Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Dengue Vaccines Key Players Headquarters & Area Served
  7. 4.4 Global Dengue Vaccines Players, Product Type & Application
  8. 4.5 Global Dengue Vaccines Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Dengue Vaccines Market CR5 and HHI
  11. 4.6.3 2025 Dengue Vaccines Tier 1, Tier 2, and Tier 3
5 Dengue Vaccines Market Size by Type
  1. 5.1 Global Dengue Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Dengue Vaccines Revenue by Type (2021-2032)
  3. 5.3 Global Dengue Vaccines Revenue Market Share by Type (2021-2032)
6 Dengue Vaccines Market Size by Application
  1. 6.1 Global Dengue Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Dengue Vaccines Revenue by Application (2021-2032)
  3. 6.3 Global Dengue Vaccines Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Dengue Vaccines Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Dengue Vaccines Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Takeda
  8. 7.2.1 Takeda Company Information
  9. 7.2.2 Takeda Business Overview
  10. 7.2.3 Takeda Dengue Vaccines Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Dengue Vaccines Product Portfolio
  12. 7.2.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Dengue Vaccines Revenue (2021-2032)
  2. 8.2 North America Dengue Vaccines Revenue by Type (2021-2032)
  3. 8.2.1 North America Dengue Vaccines Revenue by Type (2021-2026)
  4. 8.2.2 North America Dengue Vaccines Revenue by Type (2027-2032)
  5. 8.3 North America Dengue Vaccines Revenue Share by Type (2021-2032)
  6. 8.4 North America Dengue Vaccines Revenue by Application (2021-2032)
  7. 8.4.1 North America Dengue Vaccines Revenue by Application (2021-2026)
  8. 8.4.2 North America Dengue Vaccines Revenue by Application (2027-2032)
  9. 8.5 North America Dengue Vaccines Revenue Share by Application (2021-2032)
  10. 8.6 North America Dengue Vaccines Revenue by Country
  11. 8.6.1 North America Dengue Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Dengue Vaccines Revenue by Country (2021-2026)
  13. 8.6.3 North America Dengue Vaccines Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Dengue Vaccines Revenue (2021-2032)
  2. 9.2 Europe Dengue Vaccines Revenue by Type (2021-2032)
  3. 9.2.1 Europe Dengue Vaccines Revenue by Type (2021-2026)
  4. 9.2.2 Europe Dengue Vaccines Revenue by Type (2027-2032)
  5. 9.3 Europe Dengue Vaccines Revenue Share by Type (2021-2032)
  6. 9.4 Europe Dengue Vaccines Revenue by Application (2021-2032)
  7. 9.4.1 Europe Dengue Vaccines Revenue by Application (2021-2026)
  8. 9.4.2 Europe Dengue Vaccines Revenue by Application (2027-2032)
  9. 9.5 Europe Dengue Vaccines Revenue Share by Application (2021-2032)
  10. 9.6 Europe Dengue Vaccines Revenue by Country
  11. 9.6.1 Europe Dengue Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Dengue Vaccines Revenue by Country (2021-2026)
  13. 9.6.3 Europe Dengue Vaccines Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Dengue Vaccines Revenue (2021-2032)
  2. 10.2 China Dengue Vaccines Revenue by Type (2021-2032)
  3. 10.2.1 China Dengue Vaccines Revenue by Type (2021-2026)
  4. 10.2.2 China Dengue Vaccines Revenue by Type (2027-2032)
  5. 10.3 China Dengue Vaccines Revenue Share by Type (2021-2032)
  6. 10.4 China Dengue Vaccines Revenue by Application (2021-2032)
  7. 10.4.1 China Dengue Vaccines Revenue by Application (2021-2026)
  8. 10.4.2 China Dengue Vaccines Revenue by Application (2027-2032)
  9. 10.5 China Dengue Vaccines Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Dengue Vaccines Revenue (2021-2032)
  2. 11.2 Asia Dengue Vaccines Revenue by Type (2021-2032)
  3. 11.2.1 Asia Dengue Vaccines Revenue by Type (2021-2026)
  4. 11.2.2 Asia Dengue Vaccines Revenue by Type (2027-2032)
  5. 11.3 Asia Dengue Vaccines Revenue Share by Type (2021-2032)
  6. 11.4 Asia Dengue Vaccines Revenue by Application (2021-2032)
  7. 11.4.1 Asia Dengue Vaccines Revenue by Application (2021-2026)
  8. 11.4.2 Asia Dengue Vaccines Revenue by Application (2027-2032)
  9. 11.5 Asia Dengue Vaccines Revenue Share by Application (2021-2032)
  10. 11.6 Asia Dengue Vaccines Revenue by Country
  11. 11.6.1 Asia Dengue Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Dengue Vaccines Revenue by Country (2021-2026)
  13. 11.6.3 Asia Dengue Vaccines Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Dengue Vaccines Revenue (2021-2032)
  2. 12.2 SAMEA Dengue Vaccines Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Dengue Vaccines Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Dengue Vaccines Revenue by Type (2027-2032)
  5. 12.3 SAMEA Dengue Vaccines Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Dengue Vaccines Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Dengue Vaccines Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Dengue Vaccines Revenue by Application (2027-2032)
  9. 12.5 SAMEA Dengue Vaccines Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Dengue Vaccines Revenue by Country
  11. 12.6.1 SAMEA Dengue Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Dengue Vaccines Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Dengue Vaccines Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst